UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 20, 2004
Eyetech Pharmaceuticals, Inc.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50516 13-4104684
- ---------------------------- ------------- -------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Numbers) Identification No.)
3 Times Square, 12th Floor
New York, NY 10036
- ---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (212) 824-3100
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure
On September 20, 2004, Eyetech Pharmaceuticals, Inc. and Pfizer Inc.
provided a regulatory update on the use of Macugen(TM) (pegaptanib sodium
injection) in the treatment of neovascular age-related macular degeneration. The
full text of the press release issued in connection with the announcement is
filed as Exhibit 99.1 to this Current Report on Form 8-K.
The furnishing of the attached press release is not an admission as to the
materiality of any of the information set forth in this Form 8-K or the attached
press release.
The information in this Item 7.01 of Form 8-K (including the exhibit) shall
not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: September 20, 2004 EYETECH PHARMACEUTICALS, INC.
By: /s/ Glenn P. Sblendorio
----------------------------------
Name: Glenn P. Sblendorio
Title: Senior Vice President, Finance and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release dated September 20, 2004, of Eyetech
Pharmaceuticals, Inc. and Pfizer Inc. providing a regulatory
update on the use of Macugen(TM) (pegaptanib sodium
injection) in the treatment of neovascular age-related
macular degeneration.